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Abstract
Background: The aim of this study was to determine a predictive indicator of gemcitabine (GEM)
efficacy in unresectable pancreatic cancer using tissue obtained by endoscopic ultrasound-guided
fine-needle aspiration biopsy (EUS-FNA).
Methods: mRNAs extracted from 35 pancreatic tubular adenocarcinoma tissues obtained by EUS-
FNA before GEM-treatment were studied. mRNAs were amplified and applied to a Focused DNA
Array, which was restricted to well-known genes, including GEM sensitivity-related genes,
deoxycytidine kinase (dCK), human equilibrative nucleoside transporter 1 (hENT1), hENT2, dCMP
deaminase, cytidine deaminase, 5'-nucleotidase, ribonucleotide reductase 1 (RRM1) and RRM2.
mRNA levels were classified into high and low expression based on a cut-off value defined as the
average expression of 35 samples. These 35 patients were divided into the following two groups.
Patients with partial response and those with stable disease whose tumor markers decreased by
50% or more were classified as the effective group. The rest of patients were classified as the non-
effective group. The relationship between GEM efficacy and mRNA expression was then examined
by chi-squared test.
Results: Among these GEM sensitivity-related genes, dCK alone showed a significant correlation
with GEM efficacy. Eight of 12 patients in the effective group had high dCK expression, whereas 16
of 23 patients in non-effective group had low dCK expressions (P = 0.0398).
Conclusion: dCK mRNA expression is a candidate indicator for GEM efficacy in unresectable
pancreatic cancer. Quantitative mRNA measurements of dCK using EUS-FNA samples are
necessary for definitive conclusions.
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Background
Pancreatic cancer is one of the most lethal human cancers.
The standard treatment for unresectable pancreatic cancer
was previously 5-fluorouracil (5-FU)-based chemother-
apy. In 1997, however, it was reported that gemcitabine
(GEM) conferred significantly longer survival and clinical
benefits when compared to 5-FU in patients with locally
advanced or metastatic pancreatic cancer [1]. Since that
time, GEM has been recognized as the standard treatment
for this disease.
Recent investigations using cell lines or surgical specimens
have revealed that the expressions of human equilibrative
nucleoside transporter 1 (hENT1) [2-4] and the GEM-
metabolism-related enzymes such as deoxycytidine kinase
(dCK) [5,6] are putative predictors for the efficacy of GEM
treatment. If GEM could be selectively administered to
patients with GEM-sensitive tumors based on the expres-
sion of these genes in the tumor, maximum efficacy could
be achieved and the unpleasant side effects in GEM-resist-
ant patients may be avoided.
Focused DNA array (FDA), a DNA microarray restricted to
tens to hundreds of well-known genes, is an ideal tool for
comprehensive analysis of GEM sensitivity-related genes,
as it has the ability to simultaneous measure the expres-
sion of a number of genes. DNA microarray analysis has
rarely been used to study unresectable pancreatic cancer,
because obtaining pancreatic cancer cells without surgery
has traditionally been difficult. However, the recent devel-
opment of endoscopic ultrasound-guided fine-needle
aspiration (EUS-FNA) has allowed pancreatic tissue to be
obtained safely. This technique thus opens new possibili-
ties for the diagnosis of pancreatic cancer, not only by
pathology, but also by gene analysis, such as for the K-ras
mutation [7,8]. The aim of this study was to identify pos-
sible predictors of GEM efficacy using EUS-FNA samples
of unresectable pancreatic cancer by means of FDA analy-
sis.
Methods
EUS-FNA procedure
Thirty-five patients with unresectable pancreatic ductal
cancers treated with GEM were studied. EUS-FNA was per-
formed before GEM-treatment and the procedures were as
described elsewhere [9]. In brief, the lesion was identified
on B-mode imaging. The absence of vessels in the target
area was confirmed with the color Doppler mode. After
determination of the adequate angle to the tumor, an
aspiration needle was introduced into the lesion. While
the catheter connected to the needle was sucked by a 20
ml syringe, the needle was moved back and forth 20–30
times within the tumor. The negative pressure was
released before the needle was removed from the lesion.
To obtain sufficient tissue for RNA extraction and patho-
logical diagnosis, several biopsy specimens were collected
from each tumor by EUS-FNA using 19 or 22-gauge aspi-
ration needles (ECHOTIP ULTRA; Wilson-Cook Medical
Inc., Winston-Salem, NC, USA). A 19-gauge needle can
take more amount of specimen than a 22-gauge needle.
However, a 22-gauge needle gives less damage to tissue
than a 19-gauge needle and can take enough specimen for
the diagnosis and the analysis. We used 19-gauge needles
for the first nine cases. For the following 26 cases, the tis-
sues were obtained by 22-gauge needles. A cytopatholo-
gist immediately examined the specimens for cancer cells
using part of the obtained tissue.
RNA extraction
To ensure RNA quality, the obtained tissue was instantly
immersed in 1 ml of RNAlater (Ambion, Austin, TX, USA)
and incubated overnight in reagent at 4°C. Tissue samples
were then removed from RNAlater and transferred to -
80°C for storage. Total RNAs were extracted using the
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer's instructions. Amounts of
RNA were measured using a NanoDrop ND-1000 Spectro-
photometer (NanoDrop Technologies, Inc., Wilmington,
DE, USA). RNAs were examined for qualities by confirm-
ing the 28S and 18S ribosomal bands with an Agilent
2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara,
CA, USA). RNA samples were subjected to FDA analyses
after amplification.
Patients
The patients with advanced pancreatic cancer, who were
admitted to Aichi Cancer Center Hospital from Novem-
ber, 2004 to April, 2007 and were planed to treat with
GEM monotherapy, were consecutively entered into this
study. GEM monotherapy was performed for all patients
by administering intravenous GEM at a dose of 1000 mg/
m2 for 30 minutes on days 1, 8 and 15 of a 28-day cycle.
The patients were assessed for definitive GEM efficacy,
and were thus investigated for correlations between GEM
sensitivity-related gene expression and clinical efficacy of
GEM monotherapy. Clinicopahtologic data for the 35
patients are shown in Table 1. Evaluation of response to
GEM by imaging study was based on the Response Evalu-
ation Criteria in Solid Tumors (RECIST). The GEM-effec-
tive patients were defined as having a partial response
(PR) by imaging studies or as having stable disease (SD)
by imaging studies and a 50% or more decrease in both of
abnormal CA 19-9 and CEA titers in sera, as compared to
pretreatment values.
This study was performed in accordance with the human
and ethical principles of research set forth in the Helsinki
guidelines. Informed consent was obtained from all
patients who participated in the investigation. This study
was approved by the institutional review boards of OsakaJournal of Experimental & Clinical Cancer Research 2009, 28:83 http://www.jeccr.com/content/28/1/83
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City University Graduate School of Medicine and Aichi
Cancer Center.
RNA isolation linear RNA polymerase amplification
The extracted RNA from EUS-FNA sample was insufficient
for FDA analysis; therefore, RNA were amplified as
described elsewhere [10]. Briefly, the sample RNA was
subjected to reverse transcription with T7 RNA polymer-
ase-based linear amplification using the Agilent Low RNA
Input Linear Amplification Kit (Agilent Technology, Inc.)
to synthesize cDNA. The same kit was used for synthe-
sized cDNA to amplify antisense RNA (aRNA) by in vitro
transcription using T7 RNA polymerase. During this pro-
cedure, amplified aRNAs from the sample and the refer-
ence RNA (mix of RNAs from pancreatic cancer cell line
BxPC-3 and colon cancer cell line DLD-1, 1:1 ratio) were
labeled with Cyanine 5 (cy5) and Cyanine 3 (cy3) mono-
functional reactive dyes (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden), respectively.
FDA analysis
FDA included 133 genes that code sensitivity-related fac-
tors such as thymidylate synthase (TS) and dihydropyri-
midine dehydrogenase (DPD), and molecular targets such
as epidermal growth factor receptor (EGFR) and vascular
endothelial growth factor (VEGF). With regard to GEM
sensitivity-related factors, dCK, hENT1, hENT2, deoxycyti-
dylate deaminase (DCD), cytidine deaminase (CDA), 5'-
nucleotidase (5'-NT), ribonucleotide reductase 1 (RRM1)
and RRM2 were included on FDA.
Fluorescent aRNAs obtained from 35 RNA samples were
provided for FDA hybridization according to Agilent's oli-
gonucleotide microarray hybridization user's manual. The
hybridized FDA was scanned with an Agilent dual-laser
DNA microarray scanner G2565AA. Feature extraction
and data normalization were conducted with Agilent Fea-
ture Extraction software. Relative expression levels were
measured by normalizing the signal intensities of Cy5 to
those of Cy3. The mean of four replicate samples was used
for each experiment (Fig. 1). Data were expressed as rela-
tive values against a house-keeping gene, glyceraldehyde
3-phosphate dehydrogenase (GAPDH).
Statistical analysis
High mRNA expression was defined as above the average
value of the 35 RNA samples. The relationship between
mRNA expression and GEM efficacy was examined by chi-
squared test (Fisher's exact test). Survival data were esti-
mated by the Kaplan-Meier method and were examined
by log-rank test.
Results
Clinical outcome
Five of 35 patients who completed two courses of GEM
monotherapy showed PR, SD was seen in 19 patients, and
progressive disease was seen in 11 patients. Among the 19
SD patients, pretreatment values for tumor markers in two
patients were normal. Abnormal levels of tumor markers
in seven of 17 SD-patients decreased by 50% or more as
compared to pretreatment values. When GEM efficacy was
defined as PR or SD with a 50% or more decrease in tumor
markers compared to baseline, 12 patients were classified
into the effective group (Table 1). There was a significant
difference between the survival periods of the effective
and the non-effective groups (Median survival time, 16.6
months vs. 7.8 months, respectively; P = 0.0017) (Fig. 2).
RNA quantity and quality
Mean ± SD amount of total RNA from 35 tumors was 0.7
± 0.7 μg (range, 0.1 – 3.0 μg). All 35 RNA samples were of
sufficient quality (Fig. 3).
GEM sensitivity-related gene expression and clinical GEM 
efficacy
Gene expressions as relative values against GAPDH were
as follows: hENT-1, 3.88 (mean), 2.77–6.41 (range);
hENT-2, 4.04, 2.54–6.68; dCK, 3.90, 2.21–6.79; DCD,
4.61, 3.09–7.60; CDA, 2.71, 0.27–7.89; 5'-NT, 4.30,
1.35–7.23; RRM1, 2.02, 0.41–5.53; RRM2, 0.91, 0.18–
3.34. Among GEM sensitivity-related genes, dCK mRNA
expression alone predicted GEM efficacy (Table 2). Eight
of 12 tumors in the effective group had high dCK expres-
sion while 16 of 23 tumors in the non-effective group had
low dCK expression (P = 0.0398).
Discussion
EUS-FNA is widely used as a cytological and histological
diagnostic method for pancreatic cancer [8,11]. However,
there have been few reports on gene analysis of pancreatic
cancer using EUS-FNA samples [7,8,12]. In contrast, a
number of studies have demonstrated the feasibility of
DNA microarray analysis using samples obtained by FNA
in other malignancies, such as breast cancer and lung can-
cer [13-15]. At least 10 μg of total RNA is required for
Table 1: Clinical characteristics of patients receiving GEM 
monotherapy.
Number of patients 35
Age (y) Mean ± SD (Range) 61.3 ± 8.5 (46–77)
Gender Male:Female 16: 19
Location Head: Body/tail 7: 28
Follow-up time from commencement of GEM monotherapy (mo)
Median (Range) 7.7 (3.0–21.4)
Number of courses of GEM monotherapy
Mean ± SD (Range) 5.9 ± 4.0 (2–16)
GEM efficacy Effective*: Non-effective 12: 23
GEM, gemcitabine
*Effective, partial response by imaging study or stable disease by 
imaging study with 50% or more decrease in tumor markers 
compared to pretreatment valuesJournal of Experimental & Clinical Cancer Research 2009, 28:83 http://www.jeccr.com/content/28/1/83
Page 4 of 7
(page number not for citation purposes)
DNA microarray analysis [10]. Due to the low volume of
biopsy specimens obtained by EUS-FNA, it is typically
impossible to perform DNA microarray analysis using the
raw RNA extracted from these samples. However, a high-
fidelity RNA amplification protocol has recently been
established [10,16] that allows analysis of gene expression
profiles using small volumes RNA, such as those obtained
by EUS-FNA. In our series, only 0.1 – 3.0 μg of total RNA
was extracted from EUS-FNA biopsy samples.
The objective response rate of GEM monotherapy for pan-
creatic cancer has been reported to be 5–12% [1,17,18]. In
this study, PR was observed in 5 of 35 (14%) patients
treated with GEM monotherapy, which corresponds with
the response rates reported previously. The number of
patients in the GEM-effective group was too small to eval-
uate for correlations between GEM efficacy and mRNA
expression. Therefore, SD patients with a 50% or more
decrease in abnormal serum levels of tumor markers com-
pared to baseline were included in the GEM-effective
group. CA 19-9 has been shown to be correlated with clin-
ical efficacy of GEM in pancreatic cancer [19]. In this
study, the GEM-effective group had a significantly better
prognosis than the non-effective group, indicating that
the grouping based on GEM efficacy was appropriate.
GEM is transported into the cell largely via hENT1 and
partly via hENT2 [4]. It has been reported that pancreatic
cancer patients with high hENT1 protein [2] or mRNA [3]
expression in surgical specimens or biopsies have signifi-
cantly longer survival after GEM treatment, as compared
to those with low levels of hENT1. In in vitro experiments,
high hENT1 mRNA levels have been shown to be associ-
ated with GEM sensitivity, as represented by IC50 values
[20,21]. In cells, GEM is phosphorylated to its active
metabolites by dCK. Several reports have suggested that
high dCK enzyme activity may contribute to GEM sensi-
tivity in experimental settings [5] and surgical samples [6].
However, GEM is inactivated by deamination, as cata-
lyzed by DCD. CDA and 5'-NT are also a catabolic
Focused DNA array containing quadruplicate sets of oligonucleotide array sequences for 133 genes Figure 1
Focused DNA array containing quadruplicate sets of oligonucleotide array sequences for 133 genes. High repro-
ducibility of gene expression is confirmed in corresponding spots of the quadruplicate.Journal of Experimental & Clinical Cancer Research 2009, 28:83 http://www.jeccr.com/content/28/1/83
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enzymes of GEM. Therefore, resistance to GEM may be
induced by increased activity of DCD, CDA or 5'-NT
[3,5,22]. Ribonucleotide reductase, which consists of
dimerized large and small RRM1 and RRM2 subunits, is
the rate-limiting enzyme for DNA synthesis, as it is the
only known enzyme that converts ribonucleotides to
deoxyribonucleotides. GEM exerts its cytotoxicity by
inhibiting ribonucleotide reductase. High expression of
RRM1 and RRM2 has been suggested to be a mechanism
of GEM resistance [22-26]. Thus, several metabolic
enzymes and nucleoside transporters have been suggested
to affect GEM sensitivity. FDA analysis may therefore be
suitable to identify predictors of GEM efficacy by using a
very small quantity of samples taken by EUS-FNA from
unresectable pancreatic cancer, as it can simultaneously
assess the expression of multiple mRNAs related to GEM
sensitivity. Our results suggested that high dCK mRNA
expression is a predictor of GEM efficacy. In these experi-
mental settings, RNA from most samples were subjected
to FDA analysis and were not subjected to further assess-
ment. However, to confirm the relationship between dCK
mRNA expression and GEM efficacy, quantitative meas-
urement of expression by real-time reverse transcription-
polymerase chain reaction is required. In this study, other
GEM sensitivity-related gene expressions including hENT-
1 could not be proved to be predictors for GEM efficacy.
However, these gene expressions may not be totally
denied as predictors of GEM efficacy by the present study
using small number of samples. The contamination of
normal tissue into tumor tissue obtained by EUS-FNA
may also be a major obstacle to an accurate analysis.
Microdissection technique for EUS-FNA sample might be
required to avoid the normal tissue contamination.
Conclusion
In conclusion, dCK mRNA expression in EUS-FNA biopsy
specimens may be a predictor for response to GEM in
patients with unresectable pancreatic cancer. The FDA
Probability of survival for patients with unresectable pancre- atic ductal cancer stratified by gemcitabine efficacy Figure 2
Probability of survival for patients with unresectable 
pancreatic ductal cancer stratified by gemcitabine 
efficacy. Open circles, GEM-effective group. Closed circles, 
GEM-non-effective group. There is a significant difference 
between survival in the two groups.
Representative electropherogram of total RNA extracted  from pancreatic cancer obtained by endoscopic ultrasound- guided fine-needle aspiration biopsy Figure 3
Representative electropherogram of total RNA 
extracted from pancreatic cancer obtained by endo-
scopic ultrasound-guided fine-needle aspiration 
biopsy. The ratio of 28S to 18S of ribosomal RNA indicates 
good quality of total RNA.
Table 2: Correlation between gene expression and GEM efficacy 
in patients with pancreatic cancer receiving GEM monotherapy.
GEM efficacy
Gene Expression* Effective§ Non-effective P¶-value
hENT1 High 4 9 >0.9999
Low 8 14
hENT2 High 6 9 0.5374
Low 6 14
dCK High 8 7 0.0398
Low 4 16
DCD High 3 9 0.4765
Low 9 14
CDA High 4 9 >0.9999
Low 8 14
5'-NT High 4 12 0.2882
Low 8 11
RRM1 High 4 8 >0.9999
Low 8 15
RRM2 High 4 8 >0.9999
Low 8 15
GEM, gemcitabine
*Gene expression was determined as high or low based on mean 
values of 35 EUS-FNA samples.
§Effective, partial response by imaging study or stable disease by 
imaging study with 50% or more decrease in tumor markers 
compared to pretreatment value
¶P, examined by chi-squared test (Fisher's exact test)Journal of Experimental & Clinical Cancer Research 2009, 28:83 http://www.jeccr.com/content/28/1/83
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used in this study also contained molecular target genes
that may be promising for the treatment of pancreatic can-
cer. These data may be helpful for future cancer treatments
that target specific molecules.
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